Molecular Templates Inc
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for th… Read more
Molecular Templates Inc (MTEM) - Total Liabilities
Latest total liabilities as of June 2024: $19.59 Million USD
Based on the latest financial reports, Molecular Templates Inc (MTEM) has total liabilities worth $19.59 Million USD as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Molecular Templates Inc - Total Liabilities Trend (2002–2023)
This chart illustrates how Molecular Templates Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Molecular Templates Inc Competitors by Total Liabilities
The table below lists competitors of Molecular Templates Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Eastern Water Resources Development and Management PCL
STU:7ES1
|
Germany | €16.37 Billion |
|
MyHealthChecked Plc
LSE:MHC
|
UK | GBX2.78 Million |
|
Murray Income Trust Plc
OTCQB:MRRYF
|
USA | $167.37K |
|
Veltex Corporation
OTCQB:VLXC
|
USA | $3.93 Million |
|
Eureka Lithium Corp.
OTCQB:UREKF
|
USA | $138.04K |
Liability Composition Analysis (2002–2023)
This chart breaks down Molecular Templates Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.75 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.73 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Molecular Templates Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Molecular Templates Inc (2002–2023)
The table below shows the annual total liabilities of Molecular Templates Inc from 2002 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $31.17 Million | -72.34% |
| 2022-12-31 | $112.68 Million | -11.07% |
| 2021-12-31 | $126.70 Million | +57.32% |
| 2020-12-31 | $80.54 Million | +13.16% |
| 2019-12-31 | $71.17 Million | +81.33% |
| 2018-12-31 | $39.25 Million | +199.59% |
| 2017-12-31 | $13.10 Million | +198.11% |
| 2016-12-31 | $4.39 Million | -65.73% |
| 2015-12-31 | $12.82 Million | -86.12% |
| 2014-12-31 | $92.37 Million | -27.60% |
| 2013-12-31 | $127.59 Million | +23.43% |
| 2012-12-31 | $103.37 Million | +475.80% |
| 2011-12-31 | $17.95 Million | +59.43% |
| 2010-12-31 | $11.26 Million | -56.74% |
| 2009-12-31 | $26.03 Million | +735.03% |
| 2008-12-31 | $3.12 Million | -49.94% |
| 2007-12-31 | $6.23 Million | -51.33% |
| 2006-12-31 | $12.79 Million | +0.49% |
| 2005-12-31 | $12.73 Million | -78.30% |
| 2004-12-31 | $58.69 Million | +15.15% |
| 2003-12-31 | $50.97 Million | +442.58% |
| 2002-12-31 | $9.39 Million | -- |